CSL Behring

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: -

Employees: -

Market Cap: -

Website: http://www.cslbehring.com/

Clinical Trials

Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease

Phase 2

Completed

Conditions: Diabetic Kidney Disease (DKD)

Interventions: Biological: CSL346
Drug: Placebo

First Posted Date: 2020-06-05

Last Posted Date: 2023-12-06

Lead Sponsor: CSL Behring

Target Recruit Count: 114

Registration Number: NCT04419467

Locations: 🇺🇸
Valley Research - Fresno, Fresno, California, United States
🇺🇸
Riverside Nephrology Group, Riverside, California, United States
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States

and more 34 locations

Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)

Phase 2

Completed

Conditions: Coronavirus Disease 2019 (COVID-19)

Interventions: Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody
Drug: Placebo

First Posted Date: 2020-06-01

Last Posted Date: 2022-01-24

Lead Sponsor: CSL Behring

Target Recruit Count: 124

Registration Number: NCT04409509

Locations: 🇺🇸
Lahey Hospital and Medical Center, Burlington, Massachusetts, United States
🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
Holy Name Hospital, Teaneck, New Jersey, United States

and more 11 locations

Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease

Phase 1

Completed

Conditions: Sickle Cell Disease

Interventions: Biological: CSL889

First Posted Date: 2020-02-26

Last Posted Date: 2023-09-06

Lead Sponsor: CSL Behring

Target Recruit Count: 28

Registration Number: NCT04285827

Locations: 🇬🇧
Liverpool University Hospital, Liverpool, United Kingdom
🇺🇸
The Johns Hopkins Hospital, Baltimore, Maryland, United States
🇬🇧
University College London Hospital, London, United Kingdom

and more 12 locations

A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line

Phase 1

Withdrawn

Conditions: PICC-associated Thrombosis

Interventions: Drug: CSL312
Drug: Placebo

First Posted Date: 2020-02-24

Last Posted Date: 2020-03-25

Lead Sponsor: CSL Behring

Registration Number: NCT04281524

Respreeza® Self-administration and Learning Program (AmAREtTI Study)

Active, not recruiting

Conditions: Alpha-1 Antitrypsin Deficiency

First Posted Date: 2020-02-10

Last Posted Date: 2024-04-19

Lead Sponsor: CSL Behring

Target Recruit Count: 60

Registration Number: NCT04262284

Locations: 🇫🇷
CHU Lille, Lille, France
🇫🇷
Hospices Civils de Lyon, Lyon, France
🇫🇷
CHU Angers, Angers, France

and more 8 locations

Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705)

Phase 3

Active, not recruiting

Conditions: Graft Versus Host Disease (GVHD)

Interventions: Biological: Alpha-1 antitrypsin (AAT)
Drug: Placebo

First Posted Date: 2019-11-19

Last Posted Date: 2024-07-30

Lead Sponsor: CSL Behring

Target Recruit Count: 136

Registration Number: NCT04167514

Locations: 🇺🇸
Univ. of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Ohio State Univ.Medical Center, Columbus, Ohio, United States

and more 22 locations

Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)

Phase 2

Withdrawn

Conditions: Diffuse Cutaneous Systemic Sclerosis

Interventions: Biological: IgPro10
Biological: Placebo

First Posted Date: 2019-10-24

Last Posted Date: 2020-11-17

Lead Sponsor: CSL Behring

Registration Number: NCT04138485

Locations: 🇺🇸
Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States
🇺🇸
Rutgers Clinical Research Center, New Brunswick, New Jersey, United States
🇺🇸
Boston University Amyloidosis Center, Boston, Massachusetts, United States

and more 74 locations

Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)

Phase 2

Completed

Conditions: Diffuse Cutaneous Systemic Sclerosis

Interventions: Biological: IgPro20
Biological: IgPro10

First Posted Date: 2019-10-23

Last Posted Date: 2024-02-05

Lead Sponsor: CSL Behring

Target Recruit Count: 27

Registration Number: NCT04137224

Locations: 🇵🇱
Szpital Kliniczny Jezus, Warsaw, Poland
🇩🇪
Charité Universitätsmedizin Berlin, Berlin, Germany
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia

and more 6 locations

CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease

Phase 1

Terminated

Conditions: Anemia, Sickle Cell

Interventions: Biological: Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734

First Posted Date: 2019-09-17

Last Posted Date: 2021-06-18

Lead Sponsor: CSL Behring

Target Recruit Count: 1

Registration Number: NCT04091737

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers

Phase 1

Completed

Conditions: Asthma

Interventions: Biological: Human beta common receptor antagonist monoclonal antibody
Drug: Placebo

First Posted Date: 2019-09-09

Last Posted Date: 2024-01-10

Lead Sponsor: CSL Behring

Target Recruit Count: 78

Registration Number: NCT04082754

Locations: 🇩🇪
Paraxel Berlin, Berlin, Germany
🇩🇪
Fraunhofer-Institut für Toxikologie und Experimentelle Medizin ITEM, Hannover, Germany
🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy